Compared with azvudine recipients, patients in the Paxlovid group had a greater risk of Grade 1 AEs, including increased alanine aminotransferase (ALT) (p = 0.013), hypercholesterolemia (p < 0.001), and increased aspartate aminotransferase (AST) (p = 0.047). This evidence concerns the gene GPT and familial hypercholesterolemia.